請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78643完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 方啟泰(Chi-Tai Fang) | |
| dc.contributor.author | Yu-Ju Lin | en |
| dc.contributor.author | 林育如 | zh_TW |
| dc.date.accessioned | 2021-07-11T15:09:21Z | - |
| dc.date.available | 2024-08-28 | |
| dc.date.copyright | 2019-08-28 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-11 | |
| dc.identifier.citation | 1. Cohen, D. & Carter, P. Conflicts of interest. WHO and the pandemic flu 'conspiracies'. BMJ (Clinical research ed.) 340, c2912, doi:10.1136/bmj.c2912 (2010).
2. Dawood, F. S. et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12, 687-695, doi:10.1016/S1473-3099(12)70121-4 (2012). 3. Godlee, F. Conflicts of interest and pandemic flu. BMJ (Clinical research ed.) 340, c2947, doi:10.1136/bmj.c2947 (2010). 4. Nishiura, H. Case fatality ratio of pandemic influenza. Lancet Infect Dis 10, 443-444, doi:10.1016/S1473-3099(10)70120-1 (2010). 5. Organization, W. H. Considerations for assessing the severity of an influenza pandemic. Weekly epidemiological record No. 22, 197-212 (2009). 6. Nguyen-Van-Tam, J. S. & Hampson, A. W. The epidemiology and clinical impact of pandemic influenza. Vaccine 21, 1762-1768 (2003). 7. Nishiura, H., Klinkenberg, D., Roberts, M. & Heesterbeek, J. A. Early epidemiological assessment of the virulence of emerging infectious diseases: a case study of an influenza pandemic. PloS one 4, e6852, doi:10.1371/journal.pone.0006852 (2009). 8. Baker, M. G. et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 14 (2009). 9. Donaldson, L. J. et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ (Clinical research ed.) 339, b5213 (2009). 10. Fraser, C. et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science (New York, N.Y.) 324, 1557-1561, doi:10.1126/science.1176062 (2009). 11. Pebody, R. G. et al. Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 15 (2010). 12. Louie, J. K. et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. Jama 302, 1896-1902, doi:10.1001/jama.2009.1583 (2009). 13. Simon Mendez, L. et al. [Transmissibility and severity of the pandemic influenza A (H1N1) 2009 virus in Spain]. Gaceta sanitaria / S.E.S.P.A.S 25, 296-302, doi:10.1016/j.gaceta.2011.02.008 (2011). 14. Miller, E. et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet (London, England) 375, 1100-1108, doi:10.1016/s0140-6736(09)62126-7 (2010). 15. Cohen, C. et al. Elevated influenza-related excess mortality in South African elderly individuals, 1998-2005. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 51, 1362-1369, doi:10.1086/657314 (2010). 16. Johnson, N. P. & Mueller, J. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. Bulletin of the history of medicine 76, 105-115 (2002). 17. La Ruche, G. et al. The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 14 (2009). 18. Murray, C. J., Lopez, A. D., Chin, B., Feehan, D. & Hill, K. H. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet (London, England) 368, 2211-2218, doi:10.1016/s0140-6736(06)69895-4 (2006). 19. Nishiura, H. The relationship between the cumulative numbers of cases and deaths reveals the confirmed case fatality ratio of a novel influenza A (H1N1) virus. Japanese journal of infectious diseases 63, 154-156 (2010). 20. Garske, T. et al. Assessing the severity of the novel influenza A/H1N1 pandemic. BMJ (Clinical research ed.) 339, b2840, doi:10.1136/bmj.b2840 (2009). 21. Presanis, A. M. et al. The severity of pandemic H1N1 influenza in the United States, April - July 2009. PLoS currents 1, Rrn1042, doi:10.1371/currents.RRN1042 (2009). 22. Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR. Morbidity and mortality weekly report 59, 1057-1062 (2010). 23. Vaillant, L., La Ruche, G., Tarantola, A. & Barboza, P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 14 (2009). 24. Wijngaard, C. C. et al. Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children. PloS one 7, e31197, doi:10.1371/journal.pone.0031197 (2012). 25. Centers for Disease control, D. O. H., R.O.C. (Taiwan). Practical Guideline for Prevention and Control of Seasonal Influenza. 7, 22-24 (2008). 26. Centers for Disease control, D. O. H., R.O.C. (Taiwan). 2009 Focus H1N1 Pandemic Preparedness and Response. CDC Annual Report 2010 10-21 (2010). 27. Centers for Disease control, D. O. H., R.O.C. (Taiwan). Pandemic Inf luenza, National Communicable Disease Surveillance Systems, . 16-18, 32-34 (2011). 28. Yang, J.-R. Rapid SYBR Green I and modified probe real-time reverse transcription-PCR assays identify influenza H1N1 viruses and distinguish between pandemic and seaosnal strains American Society for Microbiology 47, 3714-17226 (2009 Nov.). 29. Brocklebank, J. T., Court, S. D., McQuillin, J. & Gardner, P. S. Influenza-A infection in children. Lancet (London, England) 2, 497-500 (1972). 30. Neuzil, K. M., Mellen, B. G., Wright, P. F., Mitchel, E. F., Jr. & Griffin, M. R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. The New England journal of medicine 342, 225-231, doi:10.1056/nejm200001273420401 (2000). 31. KG., N. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editos. Textbook of influenza. London: Blackwell Scidntific Publications; 1998. p. 219-266. 32. Jefferson, T. et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ (Clinical research ed.) 348, g2545, doi:10.1136/bmj.g2545 (2014). 33. Muthuri, S. G. et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. The Lancet. Respiratory medicine 2, 395-404, doi:10.1016/s2213-2600(14)70041-4 (2014). 34. Matias, G. et al. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza and other respiratory viruses 8, 507-515, doi:10.1111/irv.12258 (2014). 35. Thompson, W. W. et al. Estimates of US influenza-associated deaths made using four different methods. Influenza and other respiratory viruses 3, 37-49, doi:10.1111/j.1750-2659.2009.00073.x (2009). 36. Nishiura, H. The virulence of pandemic influenza A (H1N1) 2009: an epidemiological perspective on the case-fatality ratio. Expert review of respiratory medicine 4, 329-338, doi:10.1586/ers.10.24 (2010). 37. M., C. World now at start of 2009 influenza pandemic. World Health Organization. www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html. (June 2009). | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78643 | - |
| dc.description.abstract | 1.國際間針對2009年新型A型 H1N1 流感病毒（2009 pdm A / H1N1）引發之病例死亡率（CFR）研究，存在很大差異性。本文主要係為研究比較2009年至2011年間，台灣感染新型A型H1N1流感病毒病例的病例死亡率與感染季節性A型H3N2流感病毒的病例死亡率，加以調整干擾因素，以釐清新型A型H1N1流感病毒是否叫季節性流感病毒有更強的致死率。結果發現2009年7月至2011年6月期間我國感染新型A型H1N1流感病毒的2232位個案，比起831位感染季節性A型H3N2流感病毒個案，年齡較小，患慢性潛在疾病的個案較少。感染新型A型H1N1流感病毒病例的粗死亡率與H3N2流感病毒病例相近，在利用多變量邏輯式回歸分析後則顯示，經調整年齡，性別，慢性病史，抗病毒藥劑使用和疫苗史的影響後，新型A型H1N1流感病毒引起的致死率則顯著高於A型H3N2流感病毒（調整比值比1.2,95％信賴區間：1.0-1.9，p = 0.04）。
2.以鋁鹽作為流感大流行疫苗佐劑效用-系統性文獻回顧分析禽源性H5 / H7流感病毒有可能引發流感大流行，因此，流感大流行疫苗的使用與備製是整備工作中重要的一環。然而，人類對禽流感病毒表面抗原產生的免疫反應通常較差，因此疫苗製造過程中通常會以添加佐劑來的方式增加大流行前流感疫苗於人體產生的保護力。其中，鋁鹽是目前已經批准，安全夠且價格合理的佐劑，但其對流感疫苗的保護功效的提升程度仍未得到驗證文獻資料蒐集共有9項隨機對照試驗（2006-2013間共計有 22項臨床試驗比較資料，總計2,467名參與者）分別接種含鋁鹽佐劑H5N1疫苗與不含鋁鹽佐劑疫苗個案。單劑量含鋁鹽佐劑H5N1疫苗接種後其血清抗體生成保護率與細胞凝集抑制中和試驗的血清保護率之比為0.66（95％CI：0.53-0.83），與0.56（95％CI：0.42-0.74），且注射部位出現疼痛風險估計值為1.85（95％CI：1.56至2.19）。證據顯示，接種含鋁鹽佐劑的H5N1疫苗後，產生的血清抗體保護率比例顯著降低，且注射部位疼痛風險顯著增加，故代表鋁鹽降低了疫苗的免疫功效，但增加了接種部位出現局部反應的風險。 3.水包油乳劑佐劑流感疫苗對於兒童之接種疫苗效益討論-系統性文獻回顧分析減毒活性流感疫苗對於未曾感染過流感的健康幼兒能產生的保護效果有限，但該族群又是感染流感的高風險族群，因此，提供具有更好保護效益的流感疫苗被認為是兒童流感疫苗的重要議題。添加水包油乳劑佐劑流感疫苗是近年被認為有可能改善前揭問題的解決方式，但截至目前為止，臨床試驗產生了不一致的結果。因此本研究以系統性文獻回顧方法分析所有隨機對照試驗的疫苗功效數據（共有 3項試驗，n = 15,310）和血清抗體測驗數據（17項試驗，n = 9,062）。與無佐劑的疫苗相比，佐劑化的流感疫苗顯著有更好的保護功效（以RT-PCR接種含佐劑流感疫苗感染流感的風險為接種未含佐劑疫苗者的0.26），抗體測驗數據也顯示，對於未曾感染流感的兒童，血清抗體四倍以上上升的個案較接種未含佐劑組別的4.6-7.9倍。然而，在曾感染流感的兒童身上，則發現含佐劑和未含佐劑疫苗提供之保護效果類似。以上結果顯示，含水包油乳劑佐劑流感疫苗對於第一次接種流感疫苗的健康兒童提供更好的保護效果。 | zh_TW |
| dc.description.abstract | 1.Case Fatality Rate of 2009 Pandemic H1N1 Influenza：Using Seasonal H3N2 Influenza as Comparison Group: We aimed to compare CFRs of 2009 pdm A/H1N1 influenza cases with that of seasonal influenza A/H3N2 cases, with adjustment for confounding factors. This is a retrospective cohort study, which used all virologically confirmed cases which met the surveillance definition of severe influenza from Taiwan nationwide public health surveillance to analyze 2009 pdm A/H1N1 influenza-related mortality.A total of 2232 2009 pdm A/H1N1 cases and 831 A/H3N2 cases during the period from July 2009 to June 2011 were included. H1N1 cases were younger and less likely to have chronic underlying disease than H3N2 cases. The 2009 H1N1 cases had a similar crude CFR than H3N2 (9.2% vs. 8.5, p=0.76). Multivariate logistic regression show that after adjusting for the effect of age, sex, chronic disease history, oseltamivir use, and vaccine history, H1N1 had a significantly higher adjusted CFR than H3N2 (adjust OR 1.2, 95% CI: 1.0-1.9, p=0.04). We concluded that the virulence of H1N1/09pdm is only slightly higher than seasonal influenza, and people with comorbidity beer the most impact from the 2009 H1N1 epidemic.
2.Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis: Availability of effective vaccines is an essential part of pre-pandemic preparedness. However, avian influenza surface antigens are poorly immunogenic to humans, which necessitates the use of adjuvants to augment the immunogenicity of pre-pandemic influenza vaccines. Aluminum salts are approved, safe, and affordable adjuvants, but their adjuvanticity for influenza vaccines remains unverified. We conducted the first meta-analysis on this issue. A total of nine randomized controlled trials (2006–2013, 22 comparisons, 2,467 participants in total) compared aluminum-adjuvanted H5N1 vaccines versus non-adjuvanted counterparts. The weighted estimate for the ratio of the seroprotection rate after a single dose of H5N1 vaccine is 0.66 (95% CI: 0.53 to 0.83) by hemagglutination-inhibition assay or 0.56 (95% CI: 0.42 to 0.74) by neutralizing titer assay. The weighted estimate for the risk ratio of pain/tenderness at injection sites is 1.85 (95% CI: 1.56 to 2.19). The quality of evidence is low to very low for seroprotection and moderate for pain/tenderness, respectively. The significantly lower seroprotection rate after aluminum-adjuvanted H5N1 vaccines and the significantly higher risk of pain at injection sites indicate that aluminum salts decrease immunogenicity but increase local reactogenicity of pre-pandemic H5N1 vaccines in humans. 3.Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis:Standard inactivated influenza vaccines are poorly immunogenic in immunologically naive healthy young children. For them, there is an unmet need for better influenza vaccines. Oil-in-water emulsion-adjuvanted influenza vaccines are promising candidates, but clinical trials yielded inconsistent results. Here, we meta-analyzed all randomized controlled trials with efficacy data (3 trials, n=15,310) and immunogenicity data (17 trials, n=9,062). Compared with non-adjuvanted counterparts, adjuvanted influenza vaccines provided a significantly better protection (weighted estimate for risk ratio of RT-PCR-confirmed influenza: 0.26) and were significantly more immunogenic (weighted estimates for seroprotection rate ratio: 4.6 to 7.9) in healthy immunologically naive young children. Nevertheless, in immunologically non-naive children, adjuvanted and non-adjuvanted vaccines provided similar protection and were similarly immunogenic. These results indicated that oil-in-water emulsion adjuvant is highly effective in improving the efficacy of inactivated influenza vaccines in healthy young children at the first-time seasonal influenza vaccination. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T15:09:21Z (GMT). No. of bitstreams: 1 ntu-108-D97842001-1.pdf: 36899771 bytes, checksum: cf750ce096c6683ecd4ae1b582fd9b96 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | Abstract …………………………………………………………………………… i
中文摘要 ………………………………………………………………………… iv Chapter Ⅰ. Case Fatality Rate of 2009 Pandemic H1N1 Influenza：Using Seasonal H3N2 Influenza as Comparison Group …………………………………………… 1 1.1 Inroduction ……………………………………………………….............. 2 1.2 Methods ………………………………………………………..............… 4 1.3 Results ……………………………………………………….............. 8 1.4 Discussion ………………………………………………………..............10 1.5 Supplemental material ……………………………………………………16 Chapter Ⅱ. Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysisv …………………………………………………………24 2.1 Inroduction………………………………………………………..............25 2.2 Methods ………………………………………………………..............…26 2.3 Results………………………………………………………..............……28 2.4 Discussion ………………………………………………………..………..32 2.5 Supplemental material……………………………………………………..42 Chapter Ⅲ. Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis ………………………………………64 3.1 Inroduction ………………………………………………………………..65 3.2 Methods …………………………………………………………………66 3.3 Results …………………………………………………………………….73 3.4 Discussion ………………………………………………………………...81 3.5 Supplementary material ………………………………………………..90 | |
| dc.language.iso | en | |
| dc.subject | 水包油佐劑 | zh_TW |
| dc.subject | 大流行前疫苗 | zh_TW |
| dc.subject | 抗體測驗數據比值 | zh_TW |
| dc.subject | 流感大流行整備 | zh_TW |
| dc.subject | 疫苗效力 | zh_TW |
| dc.subject | 致死率 | zh_TW |
| dc.subject | Vaccine efficacy | en |
| dc.subject | Influenza preparedness | en |
| dc.subject | Case fatality rate | en |
| dc.subject | pre-pandemic influenza vaccines | en |
| dc.subject | Oil-in-water emulsion adjuvants | en |
| dc.subject | Ratio of the seroprotection rate | en |
| dc.title | 以實證為基礎之流感應變整備 | zh_TW |
| dc.title | Influenza preparedness: an evidence-based approach | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 溫在弘(Tzai-Hung Wen) | |
| dc.contributor.oralexamcommittee | 郭旭崧(Hsu-Sung Kuo),楊志良(Chih-Liang Yaung),張上淳(Shan-Chwen Chang),林先和(Hsien-Ho Lin) | |
| dc.subject.keyword | 流感大流行整備,致死率,大流行前疫苗,水包油佐劑,抗體測驗數據比值,疫苗效力, | zh_TW |
| dc.subject.keyword | Influenza preparedness,Case fatality rate,pre-pandemic influenza vaccines,Oil-in-water emulsion adjuvants,Ratio of the seroprotection rate,Vaccine efficacy, | en |
| dc.relation.page | 170 | |
| dc.identifier.doi | 10.6342/NTU201903067 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-08-12 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2024-08-28 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-D97842001-1.pdf 未授權公開取用 | 36.03 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。